When Patients Win, We All Win

Advancing
a New Front
in the War against Cancer

Provectus Biopharmaceuticals is
developing advanced therapies designed
to target and destroy the deadliest cancers
- melanoma, liver and breast - while
minimizing side effects

EXPLORE OUR CLINICAL TRIALS


PV-10

An Investigational Drug for Cancer

PH-10

An Investigational Drug for Psoriasis and Atopic Dermatitis

IN THE MEDIA

May 4, 2016

Growth Capital Expo 2016 Presentation Webcast and Slides Available

Slides from the presentation at Growth Capital Expo 2016 are now available.

April 12, 2016

Developments in Intralesional Therapy for Metastatic Melanoma

An article appearing in Cancer Control summarizes relevant medical literature regarding the use of intralesional therapies in metastatic melanoma.

April 6, 2016

The Checkpoint Immunotherapy Revolution

Provectus will hold its quarterly year-end 2015 financial business update conference call at 4 p.m. (EDT) March 30, 2016.

March 30, 2016

Webcast: Quarterly Year-End 2015 Financial Business Update Conference Call

Provectus will hold its quarterly year-end 2015 financial business update conference call at 4 p.m. (EDT) March 30, 2016.

March 28, 2016

BioPharma Asia Convention 2016 Presentation Slides Available

On March 23, 2016, Provectus Biopharmaceuticals presented at the BioPharma Asia Convention in Suntec City, Singapore.

March 21, 2016

Intralesional therapy 'here to stay' for melanoma

An article appearing on Healio reports on a presentation made by Sanjiv Agarwala, MD at the HemOnc Today Melanoma and Cutaneous Malignancies conference in which he discusses intralesional therapies for treating melanoma.

March 16, 2016

Provectus audit questions former CEO's travel-expense reimbursements

An article appearing in the Knoxville News Sentinel reports on the findings of an audit ordered by Provectus' board of directors concluding that there were irregularities connected with the reimbursement of travel expenses for former Chairman and Chief Executive Officer Dr. H. Craig Dees.

March 16, 2016

Webcast: Q4, Year-End 2015 Quarterly Business Update Conference Call

Provectus will hold its fourth quarter, year-end 2015 business update conference call at 4 p.m. (EDT) March 16, 2016.

March 1, 2016

Red Dye May be Effective Melanoma Treatment

An article appearing on BioPharm International discusses how the dye Rose Bengal was discovered to be a potential treatment for melanoma.

March 1, 2016

Webcast: Business Update Conference Call

Provectus Provectus will hold a conference call at 4 PM Eastern Standard Time, on Tuesday, March 1, 2016 to discuss recently announced changes in the Company's leadership stemming from the resignation of H. Craig Dees, PhD, as Chairman and CEO.

February 26, 2016

Old red dye shows promise as new cancer foe

An article appearing in Reuters Business News discusses how Provectus discovered and repurposed the small molecule dye Rose Bengal as a cancer therapy.

February 17, 2016

MicroCap Review: Provectus Biopharmaceuticals, Inc. - Reproducibility, the Hallmark of Western Science

Stock News Now reports on reproducability of PV-10 study results.

February 8, 2016

Webcast: BIO CEO and Investor Conference 2016

Provectus will present today at 3:00pm EST at the 18th Annual BIO CEO and Investor Conference.

January 29, 2016

Investing in Cancer Treatments: 5 Small-cap Companies Researching Drug Treatments

An Investment News Network article reports on a handful of select small-cap companies working on cancer treatments.

December 23, 2015

100 year old chemical could be the future of cancer treatment

In an interview with Peter Culpepper, a Pharmafile article discusses the history, status, and projected future use of Provectus' investigationl anti-cancer drug PV-10.

November 4, 2015

Webcast: Q3 2015 Quarterly Business Update Conference Call

Provectus will hold its quarterly business update conference call at 5 p.m. (EST) November 5, 2015 to provide a business update on PV-10 and PH-10 to the investment community and answer questions from investors.

October 7, 2015

Provectus Biopharmaceuticals to start two Phase III dermatology trials mid-2016, will entertain CRO pitches - exec

A BioPharm Insight article reports that Provectus' is planning two Phase III trials of PH-10 to begin in mid-2016.

October 7, 2015

PV-10 shows potential in hepatocellular carcinoma and metastatic liver disease

P&T meeting highlights for ESMO 17th World Congress on Gastrointestinal Cancer includes coverage of the Phase 1 study of PV-10 for chemoablation of hepatocellular cancer and cancer metastatic to the liver.

September 30, 2015

The Forecast Is Bright: Recent Advances in Melanoma Treatment

An article appearing in the Journal of Cutaneous Medicine and Surgery discusses recent advances in the treatment of advanced melanoma.

September 28, 2015

Provectus to study novel drug combined with Keytruda for stage IV melanoma

A Healio Dermatology article covers news that Provectus has initiated a Phase 1b/2 clinical trial of PV-10 in combination with Keytruda® for the treatment of stage IV melanoma.

more...

PRESS RELEASES

May 4, 2016

Provectus Biopharmaceuticals Will Hold Its 2016 First Quarter Business Update Conference Call on Tuesday, May 10, 2016, at 4 PM Eastern Daylight Time

Provectus announced today that it will host its 2016 first quarter business update conference call on Tuesday, May 10, 2016 at 4 pm Eastern Daylight Time.

April 28, 2016

Provectus Biopharmaceuticals Announces Publication of Two Abstracts on Research into IL PV-10 for Melanoma in Special Issue of ANZ Journal of Surgery

Provectus announced today that two abstracts related to research into IL PV-10 for treatment for melanoma have been published in a special issue of the ANZ Journal of Surgery detailing the Royal Australasian College of Surgeons 85th Annual Scientific Congress, 2-6 May 2016, in Queensland, Australia.

April 27, 2016

Provectus Biopharmaceuticals to Participate in Panel at Third International Conference on the Progress of Regenerative Medicine and Its Cultural Impact

Provectus today announced that it will be participating in a panel discussion at Cellular Horizons: The Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact. The conference will be held April 28-30, 2016, in Vatican City, and hosted by the Vatican's Pontifical Council for Culture, The Stem For Life Foundation and the STOQ (Science, Theology and the Ontological Quest) Foundation.

April 22, 2016

Provectus Biopharmaceuticals Reports Data On PV-10 in Combination Therapy and T Cell Mediated Immunity Presented at American Association for Cancer Research (AACR) Annual Meeting 2016

Provectus announced today that researchers from Moffitt Cancer Center in Tampa, Florida, presented a poster titled, "T cell Mediated Immunity After Combination Therapy with Intralesional PV-10 and Co-Inhibitory Blockade in a Melanoma Model," at the American Association for Cancer Research (AACR) Annual Meeting 2016, held at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

April 20, 2016

Provectus Biopharmaceuticals Reports Trials in Progress Abstract Accepted for Poster Presentation at ASCO Annual Meeting

Provectus today announced that an abstract titled Intralesional rose bengal for treatment of melanoma has been accepted for a poster presentation at the annual meeting of the American Society of Clinical Oncology being held in Chicago June 3-7, 2016.

March 30, 2016

Provectus Biopharmaceuticals, Inc. Reports Fourth Quarter and Year End 2015 Financial Results

Provectus today announced its financial results for the fourth quarter and year ended December 31, 2015.

March 24, 2016

Provectus Biopharmaceuticals to Host Its Quarterly Year-End 2015 Financial Business Update Conference Call Wednesday, March 30, 2016 at 4 pm (EDT)

Provectus today announced that it will host its 2015 year-end quarterly financial business update conference call on Wednesday, March 30, 2016, at 4:00 p.m. Eastern Daylight Time.

March 18, 2016

Provectus Biopharmaceuticals Announces Abstract Publicly Available for Poster Presentation on PV-10 in Combination Therapy and T Cell Mediated Immunity

Provectus announced today that the abstract for an upcoming poster presentation of data on intralesional PV-10 and co-inhibitory blockade and mechanisms of T cell mediated immunity in a melanoma model is now publicly available.

March 16, 2016

Provectus Biopharmaceuticals Amends Protocol for Phase 3 Study of PV-10 in Treatment of Locally Advanced Cutaneous Melanoma

Provectus today announced that the protocol for its phase 3 clinical trial for PV-10 as an investigational treatment for melanoma has been amended to reflect current and evolving standards of care and applicable patient population for a global study in melanoma.

March 16, 2016

Provectus Announces Results of Internal Investigation

Provectus announced today that the Audit Committee of its Board of Directors (the "Committee") has conducted an internal investigation that was initiated by the Committee in connection with the February 2016 resignation of the Company's former chief executive officer, Dr. H. Craig Dees. The Committee retained independent counsel and an advisory firm with forensic accounting expertise to assist the Committee in conducting the investigation. As part of the investigation, the Committee reviewed the Company's financial policies and procedures, including management expenses.

March 11, 2016

Provectus Biopharmaceuticals to Host Fourth Quarter, Year-End 2015 Conference Call Wednesday, March 16, 2016, at 4 PM EDT

Provectus today announced that it will host its fourth quarter and year-end 2015 conference call on Wednesday, March 16, 2016, at 4:00 p.m. Eastern Daylight Time.

March 10, 2016

Provectus Biopharmaceuticals Changes Date of Quarterly Business Update Conference Call to Wednesday March 16, 2016, at 4 pm (EDT)

Provectus today announced that it is changing the date for its fourth quarter and year-end conference call to Wednesday March 16, 2016, from March 10, 2016. The call will take place at 4 pm EDT that day.

March 1, 2016

Provectus Biopharmaceuticals Awarded Patent Extending Protection of the PV-10 Manufacturing Process

Provectus today announced that it has received a patent from the U.S. Patent and Trademark Office, U.S. Patent No. 9,273,022.

February 29, 2016

Provectus Biophamaceuticals to Host Business Update Conference Call Tuesday, March 1, 2016, at 4 PM EST

Provectus today announced that it will host a conference call at 4 PM Eastern Standard Time, on Tuesday, March 1, 2016. The purpose of the call will be to discuss recently announced changes in the Company's leadership stemming from the resignation of H. Craig Dees, PhD, as Chairman and CEO.

February 29, 2016

Provectus Biopharmaceuticals Initiating Phase 1 Study of PV-10 in Neuroendicrine Tumors Metastatic to Liver

Provectus today announced that it is initiating a protocol titled, "A Phase 1 Study to Assess the Safety, Tolerability and Effectiveness of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver in the Reduction of Biochemical Markers and Symptoms Caused by Secretory Products."

February 29, 2016

Provectus Biopharmaceuticals Announces Leadership Changes

Provectus announced today several leadership changes following the resignation of one of its Co-Founders and its Chairman and CEO, H. Craig Dees, PhD.

February 14, 2016

Provectus Biopharmaceuticals Announces Data on PV-10 and Co-Inhibitory Blockade to Be Presented at American Association for Cancer Research Annual Meeting 2016

Provectus today announced that data on intralesional PV-10 and co-inhibitory blockade in a melanoma model will be presented at the American Association for Cancer Research's ("AACR") Annual Meeting 2016 on Wednesday, April 20, 2016, from 8 am to 12 Noon Central Standard Time.

February 10, 2016

Provectus Biopharmaceuticals to Host Fourth Quarter, Year-End 2015 Conference Call Thursday, March 10, 2016, at 4 PM EST

Provectus today announced that it will host its fourth quarter and year-end 2015 conference call on Thursday, March 10, 2016, at 4:00 p.m. Eastern Standard Time.

February 3, 2016

Data on Immunology Effects of Provectus Biopharmaceuticals PV-10 in Colon Cancer Presented at 11th Annual ASC Meeting

Provectus today announced data discussing the immunologic effects of PV-10 on colon cancer cells were presented yesterday at the 11th Annual Academic Surgical Congress in Jacksonville, Florida.

February 2, 2016

Provectus Biopharmaceuticals to Present at 18th Annual BIO CEO & Investor Conference

Provectus today announced that it will present at the 18th Annual BIO CEO & Investor Conference.

more...